Therefore, the combined blockade of TGFβ and PD-1/PD-L1 may provide clinically meaningful responses in some patients with MSI and MSS CRC, possibly by making the immunosuppressive TME sensitive to ICIs. This evidence concerns the gene PDCD1 and colorectal carcinoma.